Qingzhong Hu

发表

Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.

Ulrike E. Hille, Qingzhong Hu, Carsten A. Vock, 2009, European journal of medicinal chemistry.

The Role of Fluorine Substitution in Biphenyl Methylene Imidazole‐Type CYP17 Inhibitors for the Treatment of Prostate Carcinoma

Qingzhong Hu, M. Negri, R. Hartmann, 2010, ChemMedChem.

Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.

Qingzhong Hu, M. Negri, M. Bartels, 2008, Bioorganic & medicinal chemistry.

Pharmaceutical Interfering of Neddylation as Promising Treatments for Various Cancers.

Qingzhong Hu, Qiannan Shang, Lina Yin, 2019, Current topics in medicinal chemistry.

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Qingzhong Hu, Ting Guan, Lina Yin, 2020, Chinese Chemical Letters.

Asymmetric [4+2] cycloaddition of azlactones with dipolar copper–allenylidene intermediates for chiral 3,4-dhydroquinolin-2-one derivatives

Qingzhong Hu, Jie Yu, Bingbing Sun, 2019, Tetrahedron Letters.

Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.

Qingzhong Hu, R. Hartmann, B. Dick, 2016, Biochemical and biophysical research communications.

Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.

Ulrike E. Hille, Qingzhong Hu, R. Hartmann, 2010, Journal of medicinal chemistry.

Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.

Qingzhong Hu, R. Hartmann, N. Hanke, 2013, Journal of medicinal chemistry.

1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.

Qingzhong Hu, R. Hartmann, S. Rau, 2015, European journal of medicinal chemistry.

Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.

F. Belluti, A. Bisi, S. Gobbi, 2016, Journal of medicinal chemistry.

Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.

Qingzhong Hu, R. Hartmann, M. Engel, 2013, Journal of medicinal chemistry.

Manipulations of phenylnorbornyl palladium species for multicomponent construction of a bridged polycyclic privileged scaffold

Qingzhong Hu, Lina Yin, Yu-ting He, 2022, Communications Chemistry.

Using acetone/water binary solvent to enhance the stability and bioavailability of spray dried enzalutamide/HPMC-AS solid dispersions.

Qingzhong Hu, Xiaoting Zhang, D. Ouyang, 2020, Journal of pharmaceutical sciences.

Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.

Qingzhong Hu, R. Hartmann, S. Lucas, 2012, Journal of medicinal chemistry.

CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents

Qingzhong Hu, Lina Yin, 2014, Nature Reviews Urology.

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.

Maurizio Recanatini, Andrea Cavalli, Thomas Lauterbach, 2008, Bioorganic & medicinal chemistry.

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer

Qingzhong Hu, R. Hartmann, Lina Yin, 2013, International journal of molecular sciences.

Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.

Qingzhong Hu, R. Hartmann, Lina Yin, 2013, Journal of medicinal chemistry.

Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.

Qingzhong Hu, R. Hartmann, Lina Yin, 2012, Journal of medicinal chemistry.

The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer

Qingzhong Hu, R. Hartmann, 2014 .

Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.

Qingzhong Hu, R. Hartmann, S. Rau, 2015, European journal of medicinal chemistry.

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.

Qingzhong Hu, R. Hartmann, N. Hanke, 2015, European journal of medicinal chemistry.

3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

Qingzhong Hu, R. Hartmann, Lina Yin, 2012, PloS one.

Male Men1 heterozygous mice exhibit fasting hyperglycemia in the early stage of MEN1.

Qingzhong Hu, G. Jin, Yuli Guo, 2016, The Journal of endocrinology.

Therapeutic compounds for Cushing’s syndrome: a patent review (2012-2016)

Qingzhong Hu, Lina Yin, Li Ma, 2016, Expert opinion on therapeutic patents.

Inhibition of steroidogenic cytochrome P450 enzymes as treatments for the related hormone dependent diseases

Qingzhong Hu, 2010 .

Chimera induced protein degradation: PROTACs and beyond.

Qingzhong Hu, Lina Yin, 2020, European journal of medicinal chemistry.

Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.

Qingzhong Hu, R. Hartmann, M. Menger, 2017, Journal of medicinal chemistry.

Targeting Steroidogenic Cytochromes P450 (CYPs) with 6‐Substituted 1‐Imidazolylmethylxanthones

F. Belluti, A. Bisi, S. Gobbi, 2016, ChemMedChem.

Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.

F. Belluti, A. Bisi, S. Gobbi, 2019, Bioorganic chemistry.

Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.

Qingzhong Hu, R. Hartmann, N. Hanke, 2014, Journal of medicinal chemistry.

Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.

Qingzhong Hu, R. Hartmann, Amjad Ali, 2014, Journal of medicinal chemistry.

Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.

Qingzhong Hu, R. Hartmann, Lina Yin, 2014, Journal of medicinal chemistry.

Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile

Ulrike E. Hille, Qingzhong Hu, Carsten A. Vock, 2009 .

Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis.

Qingzhong Hu, Lina Yin, Qihao Xu, 2023, Drug discovery today.

Design, Synthesis, and Biological Evaluations of Pyridyl 4,5,6,7-Tetrahydro-4,7-Methanobenzo[d]isoxazoles as Potent and Selective Inhibitors of 11β-Hydroxylase.

Qingzhong Hu, Lina Yin, Yuanyuan Xue, 2022, Journal of medicinal chemistry.

Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Michael E. Lassman, M. Struthers, Qingzhong Hu, 2015, ACS medicinal chemistry letters.

Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1.

F. Belluti, A. Bisi, S. Gobbi, 2017, European journal of medicinal chemistry.

CYP17 Inhibitors. Annulations of Additional Rings in Methylene Imidazole Substituted Biphenyls: Synthesis, Biological Evaluation and Molecular Modelling

Ulrike E. Hille, Qingzhong Hu, M. Negri, 2008, Archiv der Pharmazie.

Male Men1 heterozygous mice exhibit fasting hyperglycemia in the early stage of MEN1.

Qingzhong Hu, G. Jin, Yuli Guo, 2016, The Journal of endocrinology.

Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?

Qingzhong Hu, Lina Yin, 2013, Future medicinal chemistry.

Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition

Qingzhong Hu, R. Hartmann, Sebastian J. Krug, 2013, The Journal of Steroid Biochemistry and Molecular Biology.

Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.

Ulrike E. Hille, Qingzhong Hu, R. Hartmann, 2010, Journal of Medicinal Chemistry.

Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.

Qingzhong Hu, R. Hartmann, Amjad Ali, 2015, Journal of medicinal chemistry.

Unexpected Results of a SNAr‐Reaction. A Novel Synthetic Approach to 1‐Arylthio‐2‐naphthols.

Qingzhong Hu, R. Hartmann, V. Huch, 2013 .

Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.

Qingzhong Hu, R. Hartmann, Lina Yin, 2013, Journal of medicinal chemistry.

Sinomenine Derivatives: Synthesis, Antitumor Activity, and Apoptotic Induction in MCF‐7 Cells via IL‐6/PI3K/Akt/NF‐κB Signaling Pathway

Qingzhong Hu, Lina Yin, Jianxiong Deng, 2022, ChemMedChem.

Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.

Qingzhong Hu, R. Hartmann, A. Odermatt, 2018, European journal of medicinal chemistry.

Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.

F. Belluti, A. Bisi, S. Gobbi, 2013, Journal of medicinal chemistry.